Amendments to the claims:

Please amend claim 18 as indicated below. The following list of claims replaces all earlier versions of the claims in this application.


Claims 1-10 (Canceled)

11. (Previously Presented) A corticoid 17,21-dicarboxylic ester or corticosteroid 17-carboxylic ester 21-carbonic ester of the formula I

wherein:

- A is CHOH or CHCl in arbitrary steric arrangement, CH₂, C=O or 9(11) double bond,
- Y is hydrogen, fluorine or chlorine,
- Z is hydrogen, fluorine or methyl,
- R(1) is unsubstituted phenyl or phenyl substituted by one to three substituents selected from the group consisting of methoxy, chlorine, fluorine, methyl, trifluoromethyl, acetamino, acetaminomethyl, t-butoxy, t-butyl, 3,4-methylenedioxy, BOC-amino, amino and dimethylamino,

 (C_1-C_4) -alkyl is saturated,



R(3)

is hydrogen or α- or β-methyl.

- 12. (Previously Presented) A compound as claimed in claim 11, wherein R(2) is
- 13. (Previously Presented) A compound as claimed in claim 11, wherein A is CHOH, Y is hydrogen, Z is hydrogen, (C_1-C_4) -alkyl is C_1 -alkyl, R(1) is unsubstituted phenyl, R(2) is R(3), and R(3) is hydrogen.
- 14. (Previously Presented) A compound as claimed in claim 11, wherein A is CHOH, Y is fluorine, Z is hydrogen, (C_1-C_4) -alkyl is C_1 -alkyl, R(1) is unsubstituted phenyl, R(2) is β , and R(3) is β -methyl.
- 15. (Previously Presented) A pharmaceutical composition, which comprises an effective amount of at least one compound as claimed in claim 11, together with a pharmaceutically acceptable additive.
- 16. (Previously Presented) A method for treating dermatoses, which comprises applying to skin in need of the treatment an effective amount of at least one compound as claimed in claim 11.
- 17. (Previously Presented) A method as claimed in claim 16, wherein the dermatoses are inflammatory and allergic.

- 18. (Currently Amended) A process for preparing a compound as claimed in claim 11, which comprises reacting
 - a) a compound of the formula II

in which R(5) is OH and the remaining substituents are as defined in claim 11,

a1) with an activated carboxylic acid of the formula III,

$$R(6) - CO - (O)_n - [(C_1 - C_4) - alkyl]_m - R(1)$$
 III

in which:

n is zero,

m is zero or 1, and

(C₁-C₄)-alkyl and R(1) are as defined in claim 11, and

R(6) is CI, Br, O[-CO-(O)_n-[(C₁C₄-alkyl]_m-R(1)]₁-,

-O-C(O)-CF₃, or another activated acid radical, or

a2) with a haloformate of the formula III, in which n is 1,

m is zero or 1,

(C₁-C₄)-alkyl and R(1) are as defined in claim 11 and R(6) is Cl, Br or l, or

a3) with a carboxylic acid of the formula III itself, in which R(6) is OH, andn is zero,and the other substituents are given in formula III,

in the presence of a water-eliminating reagent,

or which comprises reacting

b) a compound of the formula II

in which R(5) is Br, I, or a sulfonic aryl ester group or sulfonic alkyl ester group, and the other substituents have the meaning given in claim 11, with a salt of a carboxylic acid of the formula III,

$$R(6) - CO - (O)_n - [(C_1 - C_4) - alkyl]_m - R(1)$$
 III

in which
R(6) is - [0⁻Me⁺], and
n is zero,

and the other substituents have the meanings given in formula III.

- 19. (Previously Presented) A process as claimed in claim 18, wherein in a1) the activated carboxylic acid of formula III is a halide or anhydride or azolide.
- 20. (Previously Presented) A process as claimed in claim 18, wherein in a3) the water eliminating reagent is DCCI.
- 21. (Previously Presented) A process as claimed in claim 18, wherein in b) the salt of the carboxylic acid of the formula III is a potassium, sodium, or trialkylammonium salt.
- 22. (Previously Presented) A process as claimed in claim 18, wherein in b) Me or R(6) is the cation of an alkali metal salt or of a trialkylammonium salt.